https://r3i.org/landmark-reconsider-lipoproteina-thresholds-for-residual-risk-in-japanese-patients/ 2026-08-30T21:54:38Z R3I en Landmark  – Reconsider lipoprotein(a) thresholds for residual risk in Japanese patients 2026-08-30T21:54:38Z Blog https://r3i.org/landmark-reconsider-lipoproteina-thresholds-for-residual-risk-in-japanese-patients/ 2026-08-30T21:54:42Z R3I en Landmark – Reconsiderar los umbrales de lipoproteína(a) para el riesgo cardiovascular residual en pacientes japoneses 2026-08-30T21:54:38Z Blog https://r3i.org/landmark-reconsider-lipoproteina-thresholds-for-residual-risk-in-japanese-patients/ 2026-08-30T21:54:43Z R3I en Landmark – 日本人患者における残余リスクのリポプロテイン(a)閾値を再考する 2026-08-30T21:54:38Z Blog https://r3i.org/focus-obicetrapib-shows-potential-in-lowering-lipoproteina/ 2026-08-30T21:26:30Z R3I en Focus  – Obicetrapib shows potential in lowering lipoprotein(a) 2026-08-30T20:53:18Z Blog https://r3i.org/focus-obicetrapib-shows-potential-in-lowering-lipoproteina/ 2026-08-30T21:05:54Z R3I en Focus – El obicetrapib podría reducir la lipoproteína(a) 2026-08-30T20:53:18Z Blog https://r3i.org/focus-obicetrapib-shows-potential-in-lowering-lipoproteina/ 2026-08-30T21:20:32Z R3I en Focus – Obicetrapibがリポプロテイン(a)低下作用を示す 2026-08-30T20:53:18Z Blog https://r3i.org/r3i-editorial-05-26/ 2026-08-30T16:03:11Z R3I en R3i Editorial 05/26 2026-08-30T16:03:11Z Blog https://r3i.org/r3i-editorial-05-26/ 2026-08-30T16:15:40Z R3I en R3i Editorial 05/26 2026-08-30T16:03:11Z Blog https://r3i.org/r3i-editorial-05-26/ 2026-08-30T16:16:06Z R3I en R3i Editorial 05/26 2026-08-30T16:03:11Z Blog